Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of TAS-303 in healthy men
NCT05621447Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAS-303 in stress urinary incontinence (SUI), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Concentrations of total radioactivity in blood and plasma at Day 22, Plasma TAS-303 concentrations at Day 22 and 6 more. Started Sep 2022; status: completed.
02
Drugs
TAS-303
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on NCT05621447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621447.